LncRNA PCAT18/miR-301a/TP53INP1 axis is involved in gastric cancer cell viability, migration and invasion

Abstract

MiR-301a is as an oncogene involved in the regulation of gastric cancer (GC) progression, but the underlying mechanism is unclear. This study was to explore the lncRNA PCAT18/miR-301a/TP53INP1 axis in regulating the GC cell proliferation and metastasis. In the present study, GC tissues and cell lines were collected for the detection of PCAT18 expression. Herein, we found that, PCAT18 is significantly decreases in human GC tissues and five GC cell lines. Overexpression of PCAT18 inhibits cell viability, invasion, and migration of GC cells and tumor growth of GC xenograft tumors. PCAT18 negatively regulates the expression level of miR-301a. The interaction between PCAT18 and miR-301a is confirmed by RIP and RNA pull down. MiR-301a mimic increases cell viability and promotes cell migration and invasion and reverses the inhibitory action of PCAT18. TP53INP1 expression is negatively regulated by miR-301a and TP53INP1/miR-301a is involved in GC viability, migration, and invasion. The promoting of PCAT18 on TP53INP1 expression is abolished by miR-301a overexpression. In conclusion, lncRNA PCAT18 acts as a tumor suppressor for GC and lncRNA PCAT18, miR-301a, and TP53INP1 comprise a signal axis in regulating GC cell proliferation, migration, and invasion.

Elevated expression of miR‐301a and its functional roles in canine oral melanoma

“…The upregulation we found in canine cancer echoes similar reports in a range of human cancers, including ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, renal cell carcinoma, hepatocellular carcinoma, cervical cancer, oesophageal cancer, breast cancer, and lung tumorigenesis. 8,[14][15][16][17][31][32][33][34] Our study also produced noteworthy findings in two COM cell lines, the metastatic LMeC and primary-site KMeC. miR-301a expression was higher in LMeC cells than KMeC cells, suggesting an association between miR-301a and metastatic COM progression.…”

lncRNA prostate cancer-associated transcript 18 upregulates activating transcription factor 7 to prevent metastasis of triple-negative breast cancer via sponging miR-103a-3p

“…PCAT18 is also abnormally expressed in migratory prostate cancer and can be used as a potential therapeutic target for the treatment of metastatic prostate cancer [ 27 ]. PCAT18 can upregulate TP53INP1 expression to inhibit metastasis of gastric cancer by sponging miR-301a [ 28 ]. These data suggest that PCAT18 plays an important role in the metastatic process of adenocarcinoma.…”

“…Our results indicate the regulatory role of PCAT18 in TNBC metastasis. Alteration of PCAT18 expression causes the impairment of colorectal cancer (CRC) and gastric cancer proliferation [ 28 , 29 ]. However, PCAT18 had a slight role in the viability of TNBC cells, implying that PCAT18 is mainly responsible for cell migration in TNBC.…”

Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo

“…For instance, two tissue-specific lncRNAs, PCAT18 and LINC01133, were enriched in normal stomach tissues and downregulated in gastric cancer (GC) [ 44 ]. PCAT18 acts as a cancer inhibitor by impairing the viability, invasion, and migration of GC cells [ 45 ]. LINC01133 inhibits the proliferation, migration, and epithelial–mesenchymal transition (EMT) of GC cells by silencing the Wnt/β-catenin pathway [ 46 ].…”